Literature DB >> 27427915

The fifth epidermal growth factor-like region of thrombomodulin exerts cytoprotective function and prevents SOS in a murine model.

T Ikezoe1,2, J Yang1, C Nishioka1, B Pan1,3, K Xu3, M Furihata4, K Nakamura5, H Yurimoto5, Y Sakai5, G Honda6, A Yokoyama1.   

Abstract

The present study found that the fifth epidermal growth factor-like domain of thrombomodulin (TME5) possesses the cytoprotective function in association with an increase in levels of anti-apoptotic myeloid cell leukemia-1 protein in an activated protein C-independent manner in human umbilical vein endothelial cells (HUVECs). Importantly, TME5 counteracted calcineurin inhibitor-induced vascular permeability and successfully prevented monocrotaline-induced sinusoidal obstruction syndrome (SOS) in a murine model. Taken together, TME5 may be useful for preventing or treating lethal complications that develop after hematopoietic stem cell transplantation such as SOS and thrombotic microangiopathy in which endothelial cell damage has a role.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27427915     DOI： 10.1038/bmt.2016.195

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


  30 in total

1.  Establishment of a standard assay method for human thrombomodulin and determination of the activity of the Japanese reference standard.

Authors:  Shingo Niimi; Tadashi Oshizawa; Masaaki Naotsuka; Sumiaki Ohba; Akira Yokozawa; Tomoyo Murata; Takao Hayakawa
Journal:  Biologicals       Date:  2002-03       Impact factor: 1.856

2.  Successful treatment of sinusoidal obstructive syndrome after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin.

Authors:  T Ikezoe; K Togitani; N Komatsu; M Isaka; A Yokoyama
Journal:  Bone Marrow Transplant       Date:  2009-08-31       Impact factor: 5.483

3.  Successful treatment of transplantation-associated thrombotic microangiopathy with recombinant human soluble thrombomodulin.

Authors:  M Sakai; T Ikezoe; K Bandobashi; K Togitani; A Yokoyama
Journal:  Bone Marrow Transplant       Date:  2009-09-21       Impact factor: 5.483

Review 4.  The role of the endothelium in the short-term complications of hematopoietic SCT.

Authors:  E Carreras; M Diaz-Ricart
Journal:  Bone Marrow Transplant       Date:  2011-04-04       Impact factor: 5.483

5.  Evidence of human thrombomodulin domain as a novel angiogenic factor.

Authors:  Chung-Sheng Shi; Guey-Yueh Shi; Yi-Sheng Chang; Huai-Song Han; Cheng-Hsiang Kuo; Che Liu; Huey-Chun Huang; Yu-Jia Chang; Pin-Shern Chen; Hua-Lin Wu
Journal:  Circulation       Date:  2005-03-28       Impact factor: 29.690

6.  Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial.

Authors:  H Saito; I Maruyama; S Shimazaki; Y Yamamoto; N Aikawa; R Ohno; A Hirayama; T Matsuda; H Asakura; M Nakashima; N Aoki
Journal:  J Thromb Haemost       Date:  2006-10-13       Impact factor: 5.824

7.  Effect of recombinant human soluble thrombomodulin on clinical outcomes of patients with coagulopathy after hematopoietic stem cell transplantation.

Authors:  Takayuki Ikezoe; Asako Takeuchi; SungGi Chi; Masato Takaoka; Kazuki Anabuki; Tsukie Kim; Mizu Sakai; Ayuko Taniguchi; Kazuto Togitani; Akihito Yokoyama
Journal:  Eur J Haematol       Date:  2013-10-01       Impact factor: 2.997

8.  Microthrombomodulin. Residues 310-486 from the epidermal growth factor precursor homology domain of thrombomodulin will accelerate protein C activation.

Authors:  D J Stearns; S Kurosawa; C T Esmon
Journal:  J Biol Chem       Date:  1989-02-25       Impact factor: 5.157

9.  Phase I study of a novel recombinant human soluble thrombomodulin, ART-123.

Authors:  S Moll; C Lindley; S Pescatore; D Morrison; K Tsuruta; M Mohri; M Serada; M Sata; H Shimizu; K Yamada; G C White
Journal:  J Thromb Haemost       Date:  2004-10       Impact factor: 5.824

10.  High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes.

Authors:  U Andersson; H Wang; K Palmblad; A C Aveberger; O Bloom; H Erlandsson-Harris; A Janson; R Kokkola; M Zhang; H Yang; K J Tracey
Journal:  J Exp Med       Date:  2000-08-21       Impact factor: 14.307
View more
  11 in total

1.  A case of thrombomodulin mutation causing defective thrombin binding with absence of protein C and TAFI activation.

Authors:  Masahiko Okada; Norio Tominaga; Goichi Honda; Junji Nishioka; Nobuyuki Akita; Tatsuya Hayashi; Koji Suzuki; Hiroyuki Moriuchi
Journal:  Blood Adv       Date:  2020-06-23

Review 2.  A Critical Analysis of Experimental Animal Models of Sinusoidal Obstruction Syndrome.

Authors:  Arvind Kumar; Richard Palek; Vaclav Liska
Journal:  J Clin Exp Hepatol       Date:  2018-07-17

3.  ICAM-1-targeted thrombomodulin mitigates tissue factor-driven inflammatory thrombosis in a human endothelialized microfluidic model.

Authors:  Colin F Greineder; Ian H Johnston; Carlos H Villa; Kandace Gollomp; Charles T Esmon; Douglas B Cines; Mortimer Poncz; Vladimir R Muzykantov
Journal:  Blood Adv       Date:  2017-08-08

Review 4.  Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies.

Authors:  Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2020-09-09       Impact factor: 2.490

5.  Potentially life-threatening coagulopathy associated with simultaneous reduction in coagulation and fibrinolytic function in pediatric acute leukemia after hematopoietic stem-cell transplantation.

Authors:  Takashi Ishihara; Keiji Nogami; Tomoko Matsumoto; Akitaka Nomura; Yasufumi Takeshita; Satoshi Ochi; Midori Shima
Journal:  Int J Hematol       Date:  2017-03-16       Impact factor: 2.490

6.  Soluble Thrombomodulin Attenuates Endothelial Cell Damage in Hepatic Sinusoidal Obstruction Syndrome.

Authors:  Satoshi Takada; Tomoharu Miyashita; Yasuhiko Yamamoto; Shunsuke Kanou; Seiichi Munesue; Yoshinao Ohbatake; Shinichi Nakanuma; Koichi Okamoto; Seisho Sakai; Jun Kinoshita; Isamu Makino; Keishi Nakamura; Hidehiro Tajima; Hiroyuki Takamura; Itasu Ninomiya; Sachio Fushida; Tetsuo Ohta
Journal:  In Vivo       Date:  2018 Nov-Dec       Impact factor: 2.155

7.  G-protein coupled receptor 15 mediates angiogenesis and cytoprotective function of thrombomodulin.

Authors:  Bin Pan; Xiangmin Wang; Chie Nishioka; Goichi Honda; Akihito Yokoyama; Lingyu Zeng; Kailin Xu; Takayuki Ikezoe
Journal:  Sci Rep       Date:  2017-04-06       Impact factor: 4.379

8.  The Biological and Clinical Relevance of G Protein-Coupled Receptors to the Outcomes of Hematopoietic Stem Cell Transplantation: A Systematized Review.

Authors:  Hadrien Golay; Simona Jurkovic Mlakar; Vid Mlakar; Tiago Nava; Marc Ansari
Journal:  Int J Mol Sci       Date:  2019-08-09       Impact factor: 5.923

9.  Cytoprotective and pro-angiogenic functions of thrombomodulin are preserved in the C loop of the fifth epidermal growth factor-like domain.

Authors:  Xiangmin Wang; Bin Pan; Goichi Honda; Xintao Wang; Yuko Hashimoto; Hiroshi Ohkawara; Kailin Xu; Lingyu Zeng; Takayuki Ikezoe
Journal:  Haematologica       Date:  2018-06-14       Impact factor: 9.941

10.  Effects of Thrombomodulin in Reducing Lethality and Suppressing Neutrophil Extracellular Trap Formation in the Lungs and Liver in a Lipopolysaccharide-Induced Murine Septic Shock Model.

Authors:  Yu Kato; Osamu Nishida; Naohide Kuriyama; Tomoyuki Nakamura; Takahiro Kawaji; Takanori Onouchi; Daisuke Hasegawa; Yasuyo Shimomura
Journal:  Int J Mol Sci       Date:  2021-05-06       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.